Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx Inc (CDNA) delivers innovative non-invasive diagnostics for transplant patient care through advanced genomics and bioinformatics. This news hub provides investors and healthcare professionals with essential updates on the company's developments in precision medicine.
Key resources include: Earnings reports detailing financial performance in transplant diagnostics, regulatory updates on FDA-cleared testing solutions, and strategic partnership announcements expanding into hematology oncology. Track clinical trial outcomes validating AlloSure® monitoring and discover operational milestones in digital health integration.
Our curated collection enables efficient tracking of CDNA's progress in reducing invasive biopsies through blood-based dd-cfDNA analysis. Stay informed about innovations in kidney, heart, and lung transplant surveillance technologies that are reshaping organ rejection management.
Bookmark this page for real-time updates on CareDx's evidence-based diagnostic solutions and their impact on transplant care standards. Verify analysis dates and consult official filings for complete context on all developments.
CareDx, Inc. (Nasdaq: CDNA) announced that underwriters for its public stock offering exercised their option to purchase 288,461 additional shares at $91.00 each, generating approximately $24.7 million in net proceeds. This follows the initial offering of 1,923,077 shares, closing on January 25, 2021. The total number of shares sold in this public offering is 2,211,538, resulting in net proceeds of around $188.7 million after expenses. Goldman Sachs and Jefferies served as joint book-running managers for the offering.
CareDx, a leader in precision medicine, has announced its participation in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference. This event will take place on February 18, 2021, at 3:30 PM EST, where the company's management will present insights about their high-value healthcare solutions for transplant patients.
Investors can tune in to the live and archived webcast through CareDx's investor relations site. The company is dedicated to developing testing services and digital healthcare solutions for transplant patients.
CareDx has announced its participation at the 2021 Transplantation and Cellular Therapy (TCT) meeting, taking place from February 8-12, 2021. The company will present four abstracts, including a collaboration with Atara Biotherapeutics on the AlloCell therapeutic. This research focuses on pharmacokinetic assessment in clinical trials. CareDx will also feature AlloHeme and AlloSeq HCT for monitoring stem cell transplant patients. Senior executives express enthusiasm for advancing cellular transplantation solutions, emphasizing the importance of their data in transforming cell therapies.
CareDx, a precision medicine company, announced the closing of its public offering of 1,923,077 shares at $91.00 each, raising approximately $164 million in net proceeds. This offering allows CareDx to strengthen its working capital and support general corporate purposes. Additionally, underwriters have a 30-day option to purchase 288,461 more shares. The company's shares are traded under the symbol CDNA.
CareDx, Inc. (Nasdaq: CDNA) has announced a public offering of 1,923,077 shares at $91.00 each, aiming for gross proceeds of $175 million. The offering, closing around January 25, 2021, includes a 30-day option for underwriters to purchase an additional 288,461 shares. Funds from the offering will be directed towards working capital and corporate purposes. Goldman Sachs & Co. LLC and Jefferies LLC lead the offering as joint book-running managers. The offering is registered under a shelf registration statement filed with the SEC.
CareDx, Inc. (Nasdaq: CDNA) announced plans to offer and sell $175.0 million of its common stock in a public offering, with a potential additional $26.25 million from underwriters' options. The funds will be allocated for working capital and general corporate purposes. Goldman Sachs & Co. LLC and Jefferies LLC are the joint book-running managers for this offering, which is subject to market conditions and regulatory approval. CareDx's common stock is traded under the ticker symbol CDNA.
CareDx, Inc. (CDNA) reported preliminary financial results for Q4 and the full year 2020, highlighting a strong revenue increase. Q4 revenue is estimated between $58.4 million and $58.6 million, a 63% rise from $35.8 million in Q4 2019. Full-year revenue is projected at $191.9 million to $192.1 million, up 51% from $127.1 million in 2019. Cash and equivalents stood at approximately $224.7 million. The company aims to continue expanding in 2021.
CareDx, Inc. (Nasdaq: CDNA) announced its acquisition of TransChart LLC, an electronic health record software provider for US transplant centers. The deal, expected to close in January 2021, will enhance CareDx's digital capabilities and expand its EMR coverage to over 90 centers. Both companies aim to improve transplant patient outcomes through data-driven solutions. The transaction emphasizes CareDx's commitment to delivering high-value healthcare solutions for transplant patients and integrating TransChart's offerings into its existing services.
CareDx presented new clinical data at the 21st Annual American Society of Transplant Surgeons Digital Winter Symposium, focusing on transplant patient care. The company sponsored two symposia featuring prominent clinical leaders discussing their experiences with AlloSure, including the ADMIRAL and MAPLE studies. Notable speakers included Dr. Jason Wellen and Dr. Sander Florman. There were three accepted abstracts highlighting CareDx solutions. CEO Reg Seeto expressed optimism about sharing important new data with the transplant community.
CareDx has announced a strategic partnership with IDbyDNA to develop AlloID, a metagenomic infectious disease testing platform tailored for transplant patients. This innovative solution aims to identify over 100 pathogens and drug resistance, enhancing care for immunocompromised organ transplant recipients. The collaboration combines AlloID with existing CareDx tools like AlloSure and AlloMap, striving for comprehensive, personalized care. The technology promises improved detection through next-generation sequencing, which is vital for managing infections in transplant patients.
